Background: Differential gene expression patterns are commonly used as biomarkers to predict treatment responses among heterogeneous tumors. However, the link between response biomarkers and treatmenttargeting biological processes remain poorly understood. Here, we develop a prognosis-guided approach to establish the determinants of treatment response. Methods: The prognoses of biological processes were evaluated by integrating the transcriptomes and clinical outcomes of~26,000 cases across 39 malignancies. Gene-prognosis scores of 39 malignancies (GEO datasets) were used for examining the prognoses, and TCGA datasets were selected for validation. The Oncomine and GEO datasets were used to establish and validate transcriptional signatures for treatment responses. Findings: The prognostic landscape of biological processes was established across 39 malignancies. Notably, the prognoses of biological processes varied among cancer types, and transcriptional features underlying these prognostic patterns distinguished response to treatment targeting specific biological process. Applying this metric, we found that low tumor proliferation rates predicted favorable prognosis, whereas elevated cellular stress response signatures signified resistance to anti-proliferation treatment. Moreover, while high immune activities were associated with favorable prognosis, enhanced lipid metabolism signatures distinguished immunotherapy resistant patients. Interpretation: These findings between prognosis and treatment response provide further insights into patient stratification for precision treatments, providing opportunities for further experimental and clinical validations.
Introduction
Heterogeneity among tumors, which leads to differential treatment responses, remains the leading challenge for effective treatment [1] . Extensive efforts have been devoted to distinguish treatment responders from non-responders. Individual genes or gene signatures are commonly used as the determinants of treatment response [2] . Yet, each gene may be involved in many distinct biological processes, rendering its biological function highly context-dependent [3, 4] . Gene signatures that contain a group of genes are more informative since they represent biological functions in defined contexts. Indeed, as genes in a signature are not functionally equal, the biological processes underlying these signatures make a major contribution to determining treatment responses [2] . Therefore, establishing gene signatures and the underlying biological processes is key to determining treatment response. However, how these response biomarkers are linked to treatment targeting biological processes remains poorly understood, which impedes the process in identifying determinants of effective treatment.
To link response biomarkers and treatment targeting biological processes, gene set-based approaches can be used [3] . Gene sets according to cellular response to chemical/genetic perturbations have previously been developed in the Molecular Signatures Database (MSigDB) [5] . As treatments act by targeting specific biological process, biological process gene sets (BPGSs) associated with particular clinical outcomes may reveal molecular features of treatment response. The prognoses of BPGSs among distinct cancer cohorts provide an opportunity to identify the underlying biological processes for treatment response. Prognostic evaluation in cancer datasets has hitherto been achieved by singlegene or signature-based approaches [2] . Recently, the PREdiction of Clinical Outcomes from Genomic (PRECOG) [6] and the Human Pathology Atlas [7] have provided a systematic approach to define the prognosis of individual genes, yet it is difficult to mine out the biological insights. Gene set analysis of gene-prognosis profiles could be an effective way to systematically evaluate the prognoses of BPGSs. The prognostic patterns of BPGSs among heterogeneous cancer types thus provide an approach to learn the determinant of prognosis as well as treatment response.
Here we report a gene-prognosis ranked Gene Set Enrichment Analysis (GSEA) [3] approach to evaluate the prognostic values of BPGSs in a variety of cancers. Based on the gene-prognosis information established from the tumor transcriptomes and clinical outcomes of~26,000 patients, we systematically evaluated the prognostic values of BPGSs across 39 distinct cancer types. We found the prognoses of BPGSs vary among cancer types, and that the transcriptional contexts are responsible for the intertumor heterogeneity caused prognostic variations. Notably, we demonstrate that the transcriptional signatures and underlying biological processes associated with prognoses of BPGSs can distinguish treatment response for both anti-proliferation treatments and immunotherapy. The prognostic landscape of BPGSs reveals interactive biological processes for treatment responses, providing a novel approach for developing precision treatment strategies through available cancer datasets.
Materials and methods

TCGA, PRECOG z-scores, pathology atlas and gene expression data
TCGA datasets for 36 malignancies were downloaded from the BROAD GDAC Firehouse (https://gdac.broadinstitute.org/). Genomewide gene-prognosis data were organized according to the meta-z score method [6] . Specifically, for each dataset, RNA-seq and clinical data were downloaded and matched. The association of each gene with survival outcomes was assessed via Cox proportional hazards regression using the 'coxph' function of the R 'survival' package. P values, z-score cox coefficients and hazard ratios with 95% confidence intervals were obtained for each gene. P values for each gene were transformed into meta-z scores. Weighted meta-z-scores were collapsed into a global meta-z-score for each gene as described (Table S1 ). In this manner, each gene is assigned a specific meta-z-score for each type of cancer, as well as a global meta-z-score across all cancer types. The z-score represents the capability of a gene to differentiate two subsets of patients with distinct survival outcomes. The 'meta-z-scores' for prognostic outcome of each gene in 39 malignancies were downloaded from the PRECOG project (http://precog.stanford.edu) [6] . Survival analysis results for all protein-coding genes in 17 TCGA major cancer types were downloaded from the pathology atlas database (http://www.proteinatlas.org/ pathology) [7] . Gene expression values for patients with distinct sensitivity to therapies were downloaded from the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo). Gene expression levels (mRNA Expression z-Scores (RNA Seq V2 RSEM)) in the TCGA datasets were downloaded from the cBioPortal database (http://www.cbioportal.org/) [8, 9] .
Gene set enrichment analysis and single sample GSEA
Genes were ordered in a decreasing fashion according to pan-cancer (unweighted) or individual cancer prognostic z-scores. Pre-defined gene sets (eight major collections, H and C1-C7) were obtained from the Molecular Signatures Database (MSigDB) [5] . Chemical and genetic perturbations (CGP) gene sets containing "target" or "response" as a
Research in context
Evidence before this study Differential gene expression patterns, defined by either experimental or data-mining efforts, are commonly used as biomarkers to predict responses in cancer patients. However, how these biomarkers are linked to treatment targeting biological processes remains poorly understood, limiting the identification of determinants for effective treatment. Treatment response is currently evaluated by the clinical outcomes of patients, a parameter that is also the primary readout for evaluating the potency of biological processes in cancer. Here we integrate the transcriptomic and clinical profiles from a variety of databases to link biomarkers and treatment targeting biological processes, thereby defining the determinants of response.
Added value of this study
Based on the hypothesis that a molecular context whereby a treatment targeting biological process correlate with an adverse clinical outcome informs features of treatment responders, we have developed an integrative strategy to establish the determinants of treatment responses. The prognoses of biological processes are defined based upon the transcriptome and clinical outcomes of distinct human malignancies. Based on the prognosis-treatment response link, we have identified principles of responses to treatments targeting both cell-proliferation and immune processes. Although high cell-proliferation rate of tumors predicted a poor prognosis, we found a favorable cell-proliferation prognosis within the context of a stress response signature, which indicates resistance to anti-proliferation treatment. Moreover, while high immune activity generally led to a favored prognosis, we showed that a lipid metabolism signature for adverse immune prognoses indicates immunotherapeutic resistance.
Implications of all the available evidence
Prognostic landscape of biological processes among cancer types provides a unique opportunity to predict vulnerabilities of distinct malignancies and to identify the molecular context responsible for treatment responses. The finding that response to treatment is dependent on the prognosis of the treatment targeting biological process provides a link for identifying treatment biomarkers. Our study proves the concept of using a prognoses guided approach to define the contextual determinants of treatment responses in cancer patients.
keyword were selected to generate a ".gmt" gene set file for analysis. A customized gene set was defined as a set of genes in specific gene signature. Ranked lists were submitted to GSEA using the 'PreRanked' tool of GSEA software [3] . Interpretation of enrichment score (ES) to prognostic value is similar to the gene expression based GSEA. For a randomly distributed gene set, ES will be relatively small, but if it is concentrated at the top (adverse prognosis) or bottom (favorable prognosis) of the list, or otherwise non-randomly distributed, then the ES will be correspondingly high. For GSEA on CCLE, cell lines were grouped as sensitive or resistant according to their sensitivity to cell-proliferation targeting compounds. Enrichment of gene sets in both groups was determined. For GSEA of GEO datasets, patients were grouped as sensitive or resistant according to the authors' instructions, and then analyzed with candidate gene sets. Significantly enriched gene sets were defined using a False Discovery Rate (FDR) q-value b0.25 and a nominal P value b.05. All analyses were performed using GSEA v2.2.1 software with the preranked list and 1000 data permutations. Leading edge genes were defined by GSEA as genes in the gene set that appear in the ranked list at, or before the point where the running sum reaches its maximum deviation from zero, interpreted as the core of a gene set that accounts for the enrichment signal.
To perform single-sample gene set enrichment (ssGSEA), normalized gene expression data (downloaded from the CCLE portal) were submitted to the GenePattern platform. The ssGSEA Projection program was used to calculate separate enrichment scores for each pairing of a sample and gene set. Samples were normalized by rank, and the weighting exponent was set as 0.75. Enrichment scores for c5.bp.v6.0 (MSigDB) gene sets were subjected to Cluster 3.0 software and both gene sets and cell lines were clustered by average linkage. A clustered heat map was analyzed and visualized by TreeView.
Biomarker validation by PROGgene and SurvExpress
Candidate gene sets were submitted to the PROGgeneV2 [10] and SurvExpress online database [11] . Distinct types of cancer, including glioblastoma multiforme (TCGA), breast cancer (TCGA), colon cancer (GSE41258), lung adenocarcinoma (TCGA), and lung squamous cell carcinoma (TCGA) were analyzed using the SurvExpress. For the Cox Survival Analysis in the SurvExpress, two risk groups (high/low risk group) were defined by the median of submitted gene set expression, with patients categorized by survival time.
Hierarchical clustering
Normalized enrichment scores (NES) of each hallmark gene set for individual cancers (Table S3) were subjected to Cluster 3.0 software and both gene set and cancer type were clustered by average linkage. A clustered heat map was analyzed and visualized by TreeView. For hierarchical clustering of z-scores or gene expression values, the z-scores or gene expression values of candidate genes were subjected to the Cluster 3.0 software, clustered by average linkage according to their correlation or the Euclidean distance, and visualized by TreeView. Clustering of gene expression values was conducted by centering genes according to mean expression values (microarrays values or mRNA Expression z-Scores), clustered by average linkage and visualized by TreeView.
Validation in the TCPA dataset
Markers for enriched processes, such as cell proliferation and the immune system, were examined by the webpage survival analysis of The Cancer Proteome Atlas project [12] (TCPA, http://app1.bioinformatics. mdanderson.org/tcpa/_design/basic/index.html). Datasets of different cancer types were examined as follows: bladder urothelial carcinoma (TCGA), breast invasive carcinoma (TCGA), colon adenocarcinoma (TCGA), glioblastoma multiforme (TCGA), head and heck squamous cell carcinoma (TCGA), kidney renal clear cell carcinoma (TCGA), brain lower grade glioma (TCGA), lung adenocarcinoma (TCGA), lung squamous cell carcinoma (TCGA), endometrial carcinoma (MDACC), ovarian carcinoma (Japan), stomach adenocarcinoma (TCGA), uterine corpus endometrioid carcinoma (TCGA) and TCGA womens cancer (combined breast, uterine and ovarian cancer). Survival plots and log-rank P-values were downloaded for further analysis.
Oncomine based signature analysis
Differential expression analyses (Cancer vs Cancer Analysis) were performed in the Oncomine database [13] . Eight signatures for distinct types of cancers defined as the top high and low expressed genes for each cancer (compared with the other cancers of the same dataset) were downloaded for signature analysis. Cellcycle Con signature (CycleC) was defined by overlapping up-regulated genes in GLIO, ASTR, MEDU and down-regulated genes in GBM; and up-regulated genes in LUSC overlapping down-regulated genes in SCLC, respectively. Cell-cycle Rev signature (CycleR) was defined by overlapping down-regulated genes in GLIO, ASTR, MEDU and upregulated genes in GBM; and down-regulated genes in LUSC overlapping up-regulated genes in SCLC, respectively (illustrated in Fig. S3e , gene lists in Table S4 ). Immune Con signature (ImmuC) was defined by overlapping up-regulated genes in NEUB, LUSC and down-regulated genes in MEDU, LUAD, respectively. Immune Rev signature (ImmuR) was defined by overlapping down-regulated genes in NEUB, LUSC and up-regulated genes in MEDU and LUAD, respectively (illustrated in Fig. S5f , gene lists in Table S6 ).
Gene ontology annotation
Gene lists of interest were submitted to the MSigDB database [5] . The overlaps between gene list and pre-defined gene sets (BP: GO biological process) were computed. P value from the hypergeometric distribution for (k-1, K, N -K, n), where k is the number of genes in the intersection of the query set with a set from MSigDB, K is the number of genes in the set from MSigDB, N is the total number of gene universe (all known human gene symbols) and n is the number of genes in the query set. FDR q-value is the false discovery rate analog of hypergeometric P-value after correction for multiple hypothesis testing according to Benjamini and Hochberg, and those gene sets with FDR q b .05 were selected.
Prognostic analysis of gene signatures
To assess the prognostic values of signatures, the normalized counts were scaled to a to z-score for each signature-gene, using the following function: z-score = ((normalized counts − mean counts across all samples)/(standard deviation of counts across all samples)). Subsequently, we used the average z-scores of all signature-genes to define a signature score for each single sample. Finally, Kaplan-Meier analysis was performed in all cases with stratification of risk sub-groups based on the median value of signature scores.
Immunet analysis
For gene set analysis, the top 200 favorable prognostic genes were analyzed using Immunet [14] gene set analysis (http://immunet. princeton.edu/geneset/). The immune networks of ImmuNet were used as features in a SVM classifier to generate gene predictions for the genes that were investigated. The resulting gene predictions and their probabilities are provided as Table S5 . The proportion of genes in the submitted gene set (GS = 1) those not in the set (GS = 0) and the randomly selected negative set (GS = −1) with SVM-Prob N0.9 were analyzed.
Expression profile analysis in CCLE
Candidate genes were analyzed using the GENE-E tool of the CCLE database [15] (http://www.broadinstitute.org/ccle/data/browseAnalyses). To identify lymphocyte specific genes, expression data in the CCLE were downloaded from the cBioPortal [8, 9] database. Unsupervised consensus clustering was performed with nonnegative matrix factorization [16] (NMF, v 0.20.6, default Brunet algorithm, 50 and 100 iterations for the rank survey and clustering runs, respectively). A preferred cluster result was selected by considering profiles of the cophenetic score for clustering solutions between 2 and 5 clusters. Profiles of genes or samples were generated by reordering with silhouette widths in the consensus clusters.
Functional immune genes
Genes in functional immune processes were identified using the Gene Expression Commons database (https://gexc.stanford.edu). Gene sets of the mouse hematopoiesis model were selected by functional immune key words (e.g., dendritic, T cell, NK cell, etc.) inquiries.
Vector constructions, lentivirus production and transfection
To knockdown PLAT, PLAU and SERPINE1 in human cancer cell lines, we constructed shRNA or scramble (shGFP) in pLKO-Tet-On vector (addgene #21915, RRID: Addgene_21915). Briefly, vector was digested by AgeI and EcoRI (Thermo Scientific) for 15 min at 37°C and recovered from agarose gel by DNA recovery kit (Tiangen). Annealed oligoes were ligated with digested vector with T4 DNA ligase (Thermo Scientific) for 2 h at room temperature. Competent Stbl3 E. coli cells were transformed with the constructs, selected and identified by Sanger sequencing. The lentiviral vector (10 μg) and the two packaging viral vectors, pMD.2G (3.3 μg) and pspPax2 (6.7 μg), were co-transfected into 293 T (RRID: CVCL_0045) cells using Lipo 2000 (ThermoFisher, #11668019, 1 μg/ μL). The virus supernatant was collected at 48 h. MDA-MB-231 (bought from ATCC, RRID: CVCL_0062) cells were transfected with virus and selected with puromycin (Sigma-Aldrich, #P8833, 2 μg/ml) for six days.
Reverse transcription PCR (RT-PCR)
Cells were treated with doxycycline (Sigma-Aldrich, #D9891, 200 ng/ml) for 72 h. Total RNA was isolated using SuperPrep Cell Lysis kit (TOYOBO, #SCQ-101) as described by manufacturer and reverse transcribed with SuperPrep RT kit for qPCR (TOYOBO, #SCQ-101) for cDNA synthesis. Target genes were detected by real time PCR in CFX96 Touch™ according to manufacturer's protocol. Transcripts were quantified relative to the housekeeping gene, GAPDH. The probes used for this study were listed in Table S7 .
Cell viability assay
Cells were maintained with doxycycline (200 ng/ml) for 72 h before vehicle (DMSO), MLN8237 (Selleckchem, #S1133, 200 nM) or Palbociclib (Sigma-Aldrich, #PZ0199-PD0332991, 500 nM) treatment. Cells were seeded in 96-well plates at a density of 3 × 10 3 cells/well, allowed to adhere overnight, and treated with vehicle (DMSO) or drug for 72 h, after which they were processed for cell viability using Cell Counting Kit-8 reagent (Dojindo Molecular Technologies, #CK04).
Each condition was performed in replicates of eight wells.
Statistical analysis
Statistical analyses were performed using SPSS version 13.0 (SPSS Inc.). Kaplan-Meier statistic and log-rank tests were performed to estimate the relevance of candidate markers in overall and disease-free survival of patients. Multivariate analysis was performed using the Cox proportional hazards model. Other P values were determined using the two-tailed Student's t-test. Significant results were defined as P b .05.
Results
A prognosis-ranked GSEA for evaluating biological processes
To identify the interactive pattern of treatment targeting biological processes, we used cancer datasets to develop a stepwise bioinformatic approach (Fig. 1a) . In this model, we proposed that response to a treatment in heterogeneous patients depends on two factors: 1) inactivation of the target and 2) prognostic contribution of the targeting biological process. An alternative treatment that successfully inactivate the target rescues type II, but not type I resistance. The mechanisms for type I resistance is key to stratifying patients and effective treatment. To this end, the prognostic values of BPGSs were used to define patient cohorts where BPGSs indicate favorable (BPGS-Fav) or adverse prognosis (BPGS-Adv). A comparative analysis between BPGS-Fav and BPGS-Adv patients was followed to establish gene signatures that distinguish BPGS-Fav from BPGS-Adv patients. Gene signatures and interacting biological processes were tested in treatment response datasets to determine their capacity to distinguish responding patients (Fig. 1b) . The prognoses for individual genes (gene-prognosis scores) were examined by integrating gene expression patterns and clinical outcomes of cancer patients [6] . The 39 cancer types whose gene-prognosis scores generated by PRECOG from microarray gene expression data (Fig. 1b , Methods) were used for examining the prognoses of gene sets. In addition, 19 TCGA datasets (PRECOG matched cancer types, in-house generated gene-prognosis scores) were selected for validation (Table S1 ). To evaluate the prognostic values of gene sets, we performed an enrichment analysis of genes sets in the gene list decreasingly ranked by gene-prognosis scores, termed prognosis-ranked GSEA here. This prognosis-ranked GSEA defined two distinct prognostic classes indicating favorable and adverse prognosis, respectively (Fig. 1b) [3, 4] . Pancancer gene-prognosis scores showed a high concordance between the TCGA and PRECOG datasets (Figs. S1a and S1b). Consistently, normalized enrichment score (NES) of the gene sets (hallmark in MSigDB These results indicate the reproducibility between PRECOG and TCGA cancer datasets and the consistency of our evaluation approach.
To examine whether prognosis-ranked GSEA is capable of identifying biologically relevant gene sets, a pan-cancer prognosis-ranked GSEA was carried out in gene sets that were up-or down-regulated by specific chemical and genetic perturbations (CGP , Table S2 ). Notably, we found the opposite enrichment scores of -up/−down gene set pairs within either favorable or adverse prognoses (Fig. 1c) . For instance, the prognostic NES for gene sets that were up-and downregulated by serum in "CHANG_SERUM_RESP" were 2.798 and − 2.331, respectively. The opposite NES values that define distinct prognostic association were prevalent among CGP gene sets. Among the 148 gene set pairs enriched in either the adverse phenotype (AdvP) or favorable phenotype (FavP), 83 (56%) exhibited the opposite NES for up-and down-regulated genes (gene sets with P b .05, FDR q b 0.25 in prognosisranked GSEA, Fig. 1d and Table S2 ). This finding is consistent with the notion that genes with opposing biological roles exhibit distinct prognostic contributions. Specifically, gene sets that were up-regulated by oncogenes such as MYC and TERT were enriched in AdvP, whereas the tumor suppressor TP53 and TFRC up-regulated gene sets were enriched in FavP (Fig. 1d ). Based upon these findings, we next explored the opposite enrichment of CGP gene set pairs in cancer type specific geneprognosis scores by prognosis-ranked GSEA. Consistently, clear examples of opposite enrichments included Aplidin (−1.860 for up genes, 2.536 for down genes), CDK4i (−1.643 for up genes, 2.674 for down genes) and Cisplatin (2.004 for up genes, −1.456 for down genes) in Ewing sarcoma, as well as MYC (2.595 for up genes, −3.316 for down genes) and KDM1A (−1.660 for up genes, 1.407 for down genes) in melanoma (Fig. S1d) . Enrichment patterns of paired gene sets that were up-or down-regulated by specific perturbations further confirmed the consistency and reproducibility of our approach.
To confirm the validity of prognostically enriched gene sets, we performed gene signature-based survival analyses in the PROGgeneV2 cancer datasets as previously reported [10] . In agreement with our findings that MYC up-regulated genes were enriched in AdvP (Fig.1d ), MYC up-regulated genes were associated with poor survival outcomes in multiple tumor cohorts (Fig. S1e) . Similar findings were obtained for EZH2 up-regulated genes and TFRC down-regulated genes (Figs. S1f and S1g). As shown in Fig.1d , genes down-regulated by Rapamycin, APLIDIN and GSK3 inhibitor SB216763 (GSK3i) were enriched in AdvP. Consistently, "Rapamycin response DN", "Response to APLIDIN DN" and "Response to GSK3 inhibitor SB216763 DN" were associated with adverse prognoses in the majority of tumor cohorts (log-rank P b .05, 41/42 datasets for Rapamycin, 43/46 datasets for GSK3i, Figs. 1e, 1f and S1h). In summary, prognostic enrichment of gene sets was consistent with their biological functions and prognostic associations, further confirming the capacity of our approach to evaluate the prognoses of biological processes.
Prognoses of biological processes vary across cancer types
To assess the prognoses of key biological processes in cancer, we performed pan-cancer prognosis-ranked GSEA in 50 hallmark gene sets (MSigDB). Consistent with previous reports [6, 7] , cellproliferation programs represented by cell-cycle related gene sets were found to be associated with adverse prognoses and enriched in AdvP, as 6 of the top 10 AdvP-enriched gene sets were cellproliferation programs (gene sets with P b .05, FDR q b 0.25, Figs. 2a, left, S2a). In contrast, immune processes represented by immunerelated gene sets were associated with favorable prognoses and enriched in FavP, as 6 of the top 10 FavP-enriched gene sets were immune processes (gene sets with P b .05, FDR q b 0.25, Figs. 2a, right, S2a). Next, the prognostic association of these processes was validated by a gene signature-based survival analysis in the PROGgeneV2 cancer datasets. Consistent with prognosis-ranked GSEA, leading edge genes of cell-proliferation programs (49 genes combining leading edge genes of E2F_TARGETS and MYC_TARGETS_V1 gene sets) were associated with adverse prognoses in 43 of 47 datasets (log-rank P b .05, Figs. 2b and 2d ). In contrast, leading edge genes of immune processes (46 leading edge genes from INTERFERON_GAMMA_RESPONSE and INTERFERON_ALPHA_RESPONSE gene sets) forecasted favorable prognoses in 13 of 15 datasets (log-rank P b .05, Figs. 2c and 2d ). In addition, "E2F targets" associated gene signature was coupled with adverse prognoses (Fig. S2b) , while "IFNG response" and "IFNA response" gene signatures defined favorable prognoses (Fig. S2c) . Collectively, these data demonstrate that cell-proliferation programs and immune processes are core processes of prognostic significance in cancer.
To characterize cancer type specific prognoses of key biological processes, we assessed the hallmark biological processes in 39 distinct PRECOG malignancies. Hierarchical clustering of prognostic NES revealed a prognostic landscape of 50 core biological processes in 39 malignancies (Fig. 2e and Table S3 ). The prognoses of individual biological processes exhibited considerable cancer type-dependent variations (Fig. S2d) . Notably, in contrast to their AdvP enrichment in major cancer types, cell-proliferation programs were enriched in FavP in colon cancer, small cell lung carcinoma and glioblastoma (cancer types labeled in blue, Fig. 2e ). Similarly, immune processes were classified as favorable processes in most cancer types, but were enriched in AdvP in bladder, pancreatic and brain cancers (cancer types labeled in red, Fig. 2e ). Prognostic enrichments of the top biological processes were validated in matched TCGA datasets (lower panel, Fig. 2e ). To confirm these findings, we assessed the prognoses of biological processes from the Gene Ontology Biological Process (GOBP gene sets from MSigDB) in 39 PRECOG malignancies (Table S3) . We found that for the majority of cancer types, immune-associated GOBP were enriched in FavP, while those cell-proliferation related GOBP were enriched in AdvP (Figs. 2f and 2g) . Consistently, cancer type dependent prognostic variations were observed in these gene sets (Figs. 2f and 2g) . In addition, cancer type dependent prognostic variations were confirmed in the combined prognostic scores of core CGP gene sets (combined scores of CGP_UP and CGP_DN gene sets, Fig. S2g ). Collectively, these findings establish the prognostic landscape of key biological processes and a distinct cancer type dependent property of prognostic association across a variety of malignancies (Fig. S2h) .
Cell-proliferation prognoses point to treatment response
The cancer-type dependent prognostic variations provide an opportunity to examine whether transcriptional context of BPGS prognosis could distinguish treatment response. To determine the representative cancer types, we defined malignancies that displayed the consistent prognoses with pan-cancer NES as Con cancers, and those that showed reversing trends as Rev cancers. The analysis was focused on the prognostic pattern of the cell-proliferation program, which is a principal treatment target in a variety of cancers. Using data from the Human Pathology Atlas [7] , we found that cancer-type dependent prognostic variations in the cell-proliferation program were consistent with prognostic NES (Fig. 2e) . Specifically, the prognoses of individual cell-proliferation leading edge genes were adverse in 11/17 cancer types, while favorable prognoses were observed in malignancies such as glioma and colon cancer (Fig. 3a) . These prognostic patterns were also validated in TCPA datasets [12] , where cell-cycle markers (cyclin B1/E) showed adverse prognoses in several cancers, but favorable in colon cancer (Figs. S3a and S3b). Similarly, cell-proliferation leading edge genes displayed elevated expression in "high risk" in breast cancer (Cell-cycle Con cancer, Fig. S3c ), but displayed lower expression in "high Fig. S3d) . Therefore, colon and brain cancers are representative Rev cancers for the cell-proliferation program.
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To characterize contextual determinants of this variation, we established the Prognosis Variation Signature (PVS) according to the six representative cancer types (GLIO, GBM, ASTR, MEDU, SCLC and LUSC). These four pairs of cell-proliferation representative cancer types (GLIO-GBM, ASTR-GBM, MEDU-GBM and SCLC-LUSC) shared similar prognostic patterns for 50 hallmark gene sets except cell-proliferation programs (Fig. 2e) . The top 200 up-regulated and down-regulated genes within each cancer type were analyzed in the Oncomine database [13] to establish the PVS (see Methods, Fig. S3e and Table S4 ). Genes that were up-regulated in cancer types with favorable cell-proliferation prognoses were defined as Cell-cycle Rev signature (CycleR), and genes up-regulated in cancer types with adverse cell-proliferation prognoses were defined as Cell-cycle Con signature (CycleC). GO annotation indicated a significant enrichment of stress response, angiogenesis and regeneration processes in CycleR, whereas synapse development was prominent in CycleC (Fig. S3f) . To test whether CycleR stratified patients displayed distinct cell-proliferation prognoses, survival analyses of cell cycle genes (GO) were performed in lung adenocarcinoma subsets classified by CycleR. In agreement with our previous results, the cell-proliferation programs were associated with a favorable prognosis in CycleR high , but not in the CycleR low patients (log-rank P = .000935, Fig. 3b ).
Next, we tested whether the PVS and underlying biological processes for the cell-proliferation program indicate response to cellproliferation targeting perturbations. To this end, cancer cell lines that were sensitive (15/823 cell lines) or resistant (15/823 cell lines) to cell-proliferation targeted reagents were defined according to treatment sensitivity data in the Cancer Therapeutics Response Portal [17, 18] . GSEA in the transcriptomic profiles (Cancer Cell Line Encyclopedia, CCLE) of representative cell lines uncovered a significant enrichment of CycleR and epithelial mesenchymal transition (EMT) gene sets in the treatment resistant phenotype (Fig. S3g) . Using single sample GSEA (ssGSEA) [19] of GOBP gene sets (MsigDB) in these cell lines, we found that enrichment scores of GOBP gene sets distinguished sensitive from resistant cells. Consistently, stress response, angiogenesis and regeneration processes were significantly enriched in the resistant phenotype (Fig. 3c) . To confirm the functional roles of stress response genes in treatment resistance, we validated three of these genes (PLAT, PLAU and SERPINE1) in MDA-MB-231 cells in response to MLN8237 (AURKA inhibitor) and Palbociclib (CDK4/6 inhibitor). Consistently, cells were more sensitive to both inhibitors after knocking-down PLAT, PLAU or SERPINE1 by conditional shRNA (Figs. 3d and S3h). These findings suggest that PVS for the cellproliferation program indicate response to cell-proliferation targeting treatments.
To determine whether PVS distinguish responders from nonresponders in patients, we inspected the transcriptional profiles of pretreated patients in eight anti-proliferation treatment-response cancer datasets (GSE106977, GSE19697, GSE41998, GSE50948, GSE5820, GSE6667, GSE66999, GSE76360) [20] [21] . GSEA in the transcriptional profiles confirmed that gene sets including CycleR, EMT, hypoxia and angiogenesis were enriched in the non-responders (Fig. 3e) . Indeed, CycleR was upregulated in non-responders (NES b 0, Fig. 3f) , and was significantly enriched in non-responders in three of them (GSEA nominal P b .05 in GSE5820, GSE76360 and GSE106977, Fig. 3f ). In addition, stress response CycleR genes distinguished resistant patients from sensitive ones in the treatment-response dataset [22] (GSE5820 and GSE32962,  Fig. S3i) . Therefore, transcriptional signatures that were defined by prognostic variation could distinguish response to anti-proliferation treatments.
Co-enriched transcriptional signatures of tumors that distinguish tumor subsets have been proposed to facilitate patient stratification [23] . To determine whether the cell-proliferation PVS is co-enriched in tumors, we explored the gene expression patterns in other cancer datasets [8, 9] and found that PVS were co-enriched in tumor subsets in multiple malignancies (Figs. 3g and 3h) . Consistent with the prognostic NES patterns, the majority of glioblastoma (Cell-cycle Rev cancer) patients expressed low levels of CycleC genes, and a larger proportion of pancreatic cancer (Cell-cycle Con cancer) patients were found to be in the CycleC high group (Fig. 3g) . Subsets of CycleR co-enriched tumors were observed in glioblastoma, pancreatic cancer and additional tumor cohorts (Figs. 3h and S3j). To determine whether CycleC and CycleR are associated with established molecular subtyping, we examined the correlation of CycleC and CycleR with molecular subtypes and IDH1 mutation in the TCGA glioblastoma dataset [24] . Interestingly, CycleC and CycleR showed a reverse pattern of correlation with glioblastoma subtypes. CycleC was expressed at higher levels in neural and proneural and lower in mesenchymal subtype, whereas CycleR was enriched in mesenchymal and lower in neural and proneural subtypes (Figs. 3i and S3k). These results are consistent with previous findings that mesenchymal subtype is associated with treatment resistance and relapse in glioblastoma [25] . In addition, CycleC was enriched IDH1 mutant subset, while CycleR was enriched in IDH1 wild-type subtype (Figs. 3j and S3l), consistent with previous report that IDH1 mutant glioblastoma patients were more sensitive to radiochemotherapy [26] . Thus, transcriptional signatures that were associated with both cell-proliferation prognosis and treatment response stratified patient subsets in multiple tumors.
Immune prognoses exhibit intrinsic intertumor variation
We next examined this prognosis-guided strategy in immunotherapy, which is at present hampered by their low response rates and a Fig. 1 . GSEA defines the prognoses of biological processes (a) Overview of the working model. Response to a treatment in heterogeneous patients depends on two factors according to the treatment-response model: 1) inactivation of the target and 2) prognostic contribution of the target. An alternative target inactivating treatment rescues type II, but not type I resistance, and the mechanisms for type I resistance is key to stratifying patients and effective treatment. The prognoses of treatment targeting biological process in distinct cancer types were evaluated by integrating transcriptomic and clinical outcomes in datasets. Gene signatures and interacting biological processes that determine prognostic variation and treatment response were established to distinguish treatment responses. PrognosisTarget, the prognostic score of treatment targeting processes. InactivationTarget, the ratio of inactivated target by specific treatment. (b) A detailed analysis workflow. Black boxes indicate input or output data and blue boxes analysis method. Based on the gene sets defined by biological processes and treatment interventions available in the MSigDB database, a method was developed that relied on the genome-wide gene-prognosis metadata (PRECOG (GEO microarray datasets) or TCGA (in-house generated RNA-seq datasets) gene-prognosis data) and GSEA algorithm. This prognosis-ranked GSEA provided an estimate of the prognostic values of biological gene sets. Metagene signatures were developed according to cancer type dependent prognostic and transcriptional features, and validated by a variety of bioinformatic resources. (c) Representative enrichment plots for chemical and genetic perturbations (CGP) gene set pairs (_UP: upregulated by perturbation, _DN: downregulated by perturbation) in prognosis-ranked GSEA (pan-cancer prognostic z-score). NES, normalized enrichment score. AdvP, Adverse Prognostic Phenotype; FavP, Favorable Prognostic Phenotype. FDR, false discovery rate. FDR and Nominal P values were defined by GSEA software. (d) Prognostic NES of 57 paired CGP gene sets in PRECOG prognosis-ranked GSEA (pan-cancer prognostic z-score). Gene sets of known oncogenes or treatment perturbations are labeled in red. Orange bars indicate "UP" (upregulated by perturbation) gene sets and blue bars indicate "DN" (downregulated by perturbation) gene sets. (e) Plots indicating -Log10HR (Hazard Ratio) and -Log10P of GSK3iDNLead and RapaDNLead genes in the TCGA and GEO datasets. Leading edge genes were defined by GSEA, which was determine as genes in the gene set that appear in the ranked list at, or before the point where the running sum reaches its maximum deviation from zero, interpreted as the core of a gene set that accounts for the enrichment signal. P values (log-rank test) and HR were determined between the two patient groups stratified by median level of expression of leading edge genes using Kaplan Meier survival analysis. Each point stands for an independent dataset. Red and blue dots indicate adverse and favorable prognosis, respectively. (f) Representative curves for Kaplan Meier analyses of patients with low (green) or high (red) GSK3iDNLead (left) RapaDNLead (right) expression (stratified by median expression, n = 249/249 for GSE62564-NEUB, n = 43/42 for TCGA-MESO and n = 253/253 for TCGA-KIRC) in the cancer datasets. P values were determined using the log-rank test. 
ImmuneLead
T C G A _ P a n C a n lack of treatment biomarkers. We found that immune processes were the highest ranked biological processes associated with favorable prognoses (higher gene expression in patients with better survival outcomes). Core immune gene sets, such as antigen presentation, lymphocyte development and activation, T cell response and natural killer (NK) cell-mediated cytotoxicity were enriched in the FavP (P b .05 in GSEA, Fig. S4a ). In addition, Gene Ontology (GO) annotation of the top 200 favorable genes (PRECOG pan-cancer) demonstrated that immune processes were highly enriched (Fig. S4b) . These top favorable genes were found to be involved in well-defined immune networks (determined by ImmuNet [14] ), such as those involved in antigen presentation, lymphocyte activation and NK cell mediated killing pathways ( Fig. S4c and Table S5 ). Pan-cancer prognosis-ranked GSEA for gene sets representing 28 immune cell subpopulations and 10 immune cell processes indicated that the prognostic NES between TCGA and PRECOG were positively correlated (Pearson r = 0.7295, P b .0001, Figs. S4d and S4e). Specifically, dendritic cells, CD8 T cells, B cells and NK cells were associated with favorable prognoses, whereas macrophage and regulatory T cells indicated adverse prognoses (Fig. S4d) . We then assessed the cancer type specific prognoses of these immune processes by prognosis-ranked GSEA in cancer type specific gene-prognosis scores. Hierarchical clustering of prognostic NES for individual cancer types confirmed that dendritic cells, CD8 T cells, B cells and NK cells were associated with favorable prognoses in the majority of the 39 malignancies (Fig. S4f) . However, adverse prognoses were observed in a subset of cancers, including pancreatic cancer, glioma and glioblastoma (red labels, Fig. S4f ). TCGA datasets confirmed the favorable prognosis of immune processes in the majority of cancers, as well as the variations across different types of cancers (Fig. S4g) . These results reveal the overall favorable prognoses of core immune processes and cancer-type dependent variations.
As inflammatory signaling in cancer cells promotes cancer progression [27] , inflammatory genes from immune gene sets that are expressed in cancer cells might confer an adverse immune prognosis. To inspect this possibility, we defined lymphocyte specific genes by expression-based non-negative matrix factorization (NMF) clustering of immune leading edge genes in the CCLE dataset (Cluster 2, left panel, Fig. S5a) . A notable portion of lymphocyte-specific leading edge genes exhibited favorable prognoses in malignancies with adverse immune prognostic NES, including breast cancer and lung adenocarcinoma, but not in cancers such as glioma (right panel, Fig. S5a) . We examined the Gene Enrichment Profiler database, performed NMF clustering and collected a subset of 32 Lymphocyte Specific Functional genes (LSF genes, Fig. S5b ). Similar to the prognoses of immune cell gene sets (Figs. S4f and S4g), the prognoses of favorable LSF gene sets again varied among cancer types (Fig. 4a) . The prognostic patterns of immune process were substantiated in representative cancer datasets from the SurvExpress [11] , with immune leading edge genes indicating "low risk" in lung squamous cell carcinoma patients (Immune Con cancer, Fig. S5c ), but "high risk" in glioblastoma (Immune Rev cancer, Fig. S5d) . Moreover, survival outcomes of individual immune leading edge genes were favorable in 13/17 cancer types whereas adverse prognoses were observed in malignancies such as glioma and pancreatic cancer according to datasets from the Human Pathology Atlas [7] (Fig. S5e) . Therefore, non-hematopoietic specific gene sets partially contribute to adverse immune prognoses in certain situations, but not in malignancies such as brain cancers.
Immune interactive processes for treatment response
To uncover key factors that were responsible for immune prognostic variations, we established the immune PVS by combining transcriptional signatures of tumors from representative cancer types (MEDU, NEUB, LUSC and LUAD) in the Oncomine database [13] . These two pairs of immune representative cancer types (MEDU-NEUB and LUSC-LUAD) exhibited similar prognostic patterns for the 50 hallmark gene sets, with the exception of immune processes (Fig. 2e) . The top 300 up-regulated and down-regulated genes of representative cancer types were combined to generate the gene signatures associated with prognoses ( Fig. S5f and Table S6 ). Genes up-regulated in malignancies with adverse immune prognoses were defined as Immune Rev signature (ImmuR), and genes up-regulated in malignancies with favorable immune prognoses as Immune Con signature (ImmuC). GO annotation of these signatures indicated a significant enrichment of lipid metabolism, regulatory T cell (Treg) and macrophage processes in the ImmuR, while T-cell activation process was in the ImmuC (Fig. S5g) . To test whether patients stratified by PVS displayed distinct prognoses of immune processes, we performed survival analysis of immune genes (GO) in patient subsets classified by the ImmuC and ImmuR signatures, respectively. Consistently, the immune processes were associated with adverse prognoses in the ImmuR high patients (Fig. 4b) , whereas the immune processes were correlated with favorable prognoses in the ImmuC high patients (Fig. 4c) .
Encouraged by results from the cell-proliferation program, we speculated that immune PVS may inform treatment response in immunotherapies. To test this possibility, we performed ssGSEA on transcriptional profiles of individual patients treated with anti-PD-1 immunotherapy (GSE78220 [23] , GSE67501 [28] , GSE91061 and Aa5951 [29] ). In agreement with our hypothesis, enrichment scores for ImmuC/ImmuR (combined ssGSEA score for ImmuC and ImmuR) were significantly higher in responders than non-responders (Student's t-test, P = .097, 0.040, 0.008 and 0.0201, respectively, Fig. 4d ). We carried out GSEA of ImmuC, ImmuR and hallmark gene sets in grouped patients (responders vs non-responders) in each dataset. Consistent with the report that EMT is associated with immunotherapy resistance, EMT was found to be enriched in the immunotherapy non-responder phenotype (GSE78220, P = .004 in GSEA, Fig. S5h ) [23] . The ImmuR leading edge genes, especially MGLL that is involved in membrane lipid metabolism processes, were up-regulated in immunotherapy-resistant patients (Fig. 4e) . Notably, ImmuR was enriched in the immunotherapy non-responder phenotype (P = .040, 0.046 and 0.081 in GSEA, upper panel, Fig. 4f ), whereas ImmuC was enriched in the responder population (P = .108, 0.053 and 0.155 in GSEA, lower panel, Fig. 4f ). Indeed, among hallmark gene sets, ImmuC, ImmuR and lipid metabolic Fig. 2 . The prognostic landscape of biological processes in cancer (a) The NES of hallmark biological processes in prognosis-ranked GSEA (pan-cancer prognostic z-score). NES values were generated for all of the 50 GSEA hallmark processes using the decreasingly ranked pan-cancer prognostic z-scores. Gene sets enriched in adverse (NES N 0, left) and favorable (NES b 0, right) prognoses were ranked by NES. Red: cell-proliferation related gene sets. Blue: immune gene sets. FDR and Nominal P values were defined by GSEA software. (b) and (c) Plots indicating -Log10HR and -Log10P of the cell-proliferation programs (b) and immune processes (c) in the TCGA and GEO datasets. CycleLead here includes the 49 leading edge genes from the E2F_TARGETS and MYC_TARGET_V1 whereas the ImmuneLead here includes 46 leading edge genes from the INTERFERON_GAMMA and INTERFERON_ALPHA gene sets. P values and hazard ratios were determined by Kaplan Meier survival analyses of leading edge genes (patients were stratified by median gene expression). Each point stands for an independent dataset. Red and blue dots indicate adverse and favorable prognoses, respectively. (d) Representative curves for Kaplan Meier analyses of patients with low (green) or high (red) CycleLead (upper) or ImmuneLead (lower) expression in the GEO datasets (patients were stratified by median gene expression, n = 249/249 for GSE62564-NEUB, n = 148/147 for NKI-BRC, n = 253/253 for TCGA-KIRC, n = 82/81 for TCGA-SKCM and n = 40/40 for GSE10141-LIHC). P values were determined using the log-rank test. (e) Upper panel: Hierarchical clustering of prognostic NES for 50 hallmark gene sets in 39 malignancies. Abbreviations for cancer types are listed in Table S1 . NES for the 50 hallmark gene sets were calculated in the GSEA software according to the prognostic z-scores of each cancer type that were download from the PRECOG website. Cancers with cell-proliferation programs conferring a favorable prognosis were marked in blue whereas those with immune processes indicating poor prognosis were marked in red. Lower panel: Hierarchical clustering of NES for 6 representative gene sets in 19 TCGA datasets whose prognostic z-scores were generated in this study (See Methods). Sidebar, NES index for adverse (red) and favorable (green) prognoses. (f) and (g) Plots depicting prognostic NES of immune (f) and cell-proliferation (g) related GO processes assessed in 39 individual cancer types. Significant enrichments (P b.05, FDR q b0.25) for each gene set is labeled in red (AdvP) and blue (FavP), respectively. signatures were consistently enriched in these datasets (Fig. 4g) . These results led us to propose that transcriptional signatures and the underlying biological processes that define immune prognostic variations are associated with clinical response to immunotherapies.
To test whether these immune PVS distinguish patient subsets in a general fashion, we explored expression of ImmuC and ImmuR signatures in a panel of TCGA datasets. Indeed, ImmuC genes were co-expressed and classified into distinct transcriptional subsets in multiple types of cancer (Figs. 4h and S5i) . The ImmuR signature, which was expressed at low levels in melanoma patients (Fig. S5j) , defined an ImmuR high (high expression of ImmuR signature) subset in lung cancers (Fig. 4i) (Figs. 4h and 4i ). These findings established that the prognoses of immune processes are dependent on specific transcriptional contexts of tumors that are applicable to distinguish immunotherapy response. In summary, these conglomerate analyses reinforce the concept that prognosis of treatment targeting biological process is an indicator for treatment response. By integrating transcriptomic profiles and clinical parameters, this study presents an approach to establish transcriptional signatures and underlying biological processes as determinants that distinguish treatment responders across multiple cancers (Fig. 4j ).
Discussion
Distinguishing treatment responders from non-responders is the leading challenge to effective treatment of cancer patients. Intensive experimental and data-mining efforts has been devoted to establish differentially expressed gene patterns to distinguish responsive patients. However, how this response biomarkers are linked to treatment targeting biological processes remains poorly understood. Inspired by the fact that clinical outcomes are the primary readout for the evaluation treatment efficacy, we have developed a prognosis based strategy to define treatment biomarkers. Current approaches for prognoses of gene sets can be affected by the absolute level of gene expression, leading to biased results that are dominated by genes that are abundantly expressed in the gene set [4] . Here we linked geneprognosis profiles to biological processes through prognosis-ranked GSEA. The prognosis-ranked GSEA approach is validated by the finding that biologically paired gene sets are consistently enriched, both in pan-cancer and cancer specific gene-prognosis profiles. This systematic approach establishes a prognostic landscape of biological processes that uncovers both general and cancer type specific prognostic patterns across 39 distinct malignancies. Based on the prognostic patterns, a comparative analysis of patient cohorts with distinct prognostic patterns establishes transcriptional signatures that distinguish patients cohorts. Notably, transcriptional signatures that define intertumor prognostic variations of treatment targeting biological processes distinguish treatment response, a concept that is proved in both cellproliferation and immune processes.
The prognoses of biological processes showed both general and cancer-type specific patterns that are consistent with the oncogenic or tumor suppressive roles of these processes. Biological processes, such as cell-proliferation programs, mTORC1 signaling, the unfolded protein response and glycolysis, are frequently associated with adverse prognoses. By contrast, immune processes, TP53 pathway and apoptosis process are linked to favorable prognoses. Notably, the prognoses of all gene sets are context dependent among different cancer types. Cell-proliferation programs, which are the primary targets for current anti-cancer therapeutics, generally confer poor outcomes but signify favorable prognoses in glioblastoma and colon cancer. Similarly, immune processes indicate favorable outcomes in cancers, such as melanoma and lung cancer, yet the same immune processes suggest poor prognoses in pancreatic and a number of brain cancers. These prognostic variations may result from differences in cell-of-origin, oncogenic drivers and microenvironment among different cancer types [1] . For instance, enriched cancer stem-like cells may contribute to favorable prognoses of cell-proliferation markers in brain cancer types, as stemlike cells are slow-cycling (low cell-proliferating activity) and responsible for treatment resistance and relapse [30] . Both tumor intrinsic and microenvironmental heterogeneity may contribute to the prognostic variations of immune processes. Pancreatic cancer and glioblastoma are characterized by infiltrating immune suppressive cells, which may contribute to adverse prognoses of immune processes in these cancer types [31] [32] [33] . The prognostic variations not only strengthen the importance of our cancer type-specific prognostic resource, but also provide an opportunity to establish the determinants for prognosis and treatment response.
Tumor heterogeneity presents daunting challenges to the development of biomarkers and treatments for cancer [1] . To examine the potential of our approach in identifying treatment biomarkers, we focused on the cell-proliferation program, the primary target of cancer treatment [34] . Enrichment of stress response processes in CycleR is in accordance with the concept that cell-cycle activation in the context of stress impairs cell survival [35, 36] . The enrichment of CycleR and stress response processes in the anti-proliferation non-responder phenotype in multiple datasets demonstrates the consistency of our approach. A consistent correlation with molecular subtypes of glioblastoma further confirms the clinical significance of these signatures [24] . In addition, co-enrichment of PVS in patients indicates that transcriptional programs distinguishing prognostic patterns and treatment response exist across multiple cancers. As anti-proliferative treatments are the primary anti-cancer strategies [37] [38] [39] , these transcriptional signatures 
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and underlying biological processes have significant implications for patient stratification and effective treatment. The concept that PVS distinguishes treatment response has now been proven, and this is not limited to cell-proliferation program. This approach may also be applicable to treatments targeting other biological processes, especially treatments that are newly approved or under preclinical development, thereby providing a strategy for patient stratification based on existing cancer datasets.
Immunotherapy is now being evaluated in a wide range of cancers [38, 39] , yet the predictors and mechanisms of response remains poorly understood. For example, mutational loads have been demonstrated to benefit anti-CTLA4 responses in melanoma [40] and anti-PD1 response in lung cancer [41, 42] , while another study reports that mutational loads benefit survival, but not anti-PD-1 response [23] . The limited patient numbers may contribute to the substantial inconsistencies between these studies [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] . In contrast, our approach establishes transcriptional signatures and the underlying biological processes based on the molecular profiles of~26,000 cases, and are applicable in multiple independent datasets. This high levels of consistency indicates a general mechanism of immunotherapy responses. Specifically, the T cell activation processes that are critical for successful immunotherapy [53] , are enriched in ImmuC. Similarly, enrichment of Treg and lipid metabolism processes in ImmuR is consistent with the immunosuppressive function of Treg [54] and requirement for lipid uptake and metabolism for survival of tissue-resident memory T cells [55] . Indeed, lipid metabolism controls the functional switch between immune protection and disease state in T cells [56] . Interestingly, cancer types with favorable immune prognoses, such as melanoma and lung cancer, are responsive to immunotherapies [38, 39, 57] , whereas cancer types with adverse immune prognoses, such as pancreatic and several brain cancers, show a poor response to immunotherapy [58] . These findings further confirm a link between prognosis of treatment targeting process and treatment response.
The findings that prognoses are linked to treatment responses for specific biological processes may be useful for repurposing currently available targets and treatments based on the prognoses of related biological processes. The prognosis-repurposed vulnerabilities provide a resource of both therapeutic targets (e.g., MYC, EZH2, CDK4) and interventions (e.g., Rapamycin, Aplidin, Darapladib) that will facilitate development of novel therapeutic approaches across 39 human malignancies. This cancer type-dependent property of treatment response establishes resources that repurpose established treatments in specific cancer types. Identifying therapeutic vulnerabilities for cancers, especially those malignancies for which there are currently no effective treatments, is urgently needed. Therefore, our analysis also has the important advantage of presenting valuable resources indicative of potential treatment approaches for distinct malignancies. Although we have tried our best to optimize these analyses by keeping the versions of data consistent among different online tools and databases, there're still several limitations in this study. Firstly, the prognostic analyses here are based on overall survival because the lack of recurrence-free survival information, which is more relevant to treatment response in cancer datasets. Secondly, the prognostic landscape built by GSEA is more exploratory and less accurate as predictive biomarkers here, and more efforts are needed before their clinical application [4] . Thirdly, although several findings from our analyses are consistent with previous experimental publications, we provided only cell-based experimental validations of CycleR signature. Since both tumor-specific and immune cell-specific factors should be considered in responses to immunotherapy [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] , immune signatures are not experimentally validated because responses to immunotherapy are not well recapitulated in cell based experiments in vitro. Future in vivo studies will be considered for cell-proliferation, immune processes and other biological processes of potential interest.
Collectively, by integrating transcriptomic profiles, clinical outcomes and biological processes, we have now characterized the prognostic landscape of biological processes for a variety of cancers. These prognoses show intertumor variation patterns, which is a valuable property needed to define representative cancer types and transcriptional determinants of prognostic variation. This link between prognosis and treatment response establishes a strategy to stratify sensitive and resistant patients using transcriptional signatures that define prognostic variations. The concept that prognosis of target distinguishes treatment response may be applicable to a variaty of treatments, providing potential biomarkers for further experimental and clinical validations. These findings highlight the utility of bioinformatic resources to develop biomarkers and treatment strategies that will allow more precisely targeted and immune therapies for cancer patients.
Supplementary data to this article can be found online at https://doi. org/10.1016/j.ebiom.2019.01.064.
